Press Release: Beyfortus real-world evidence published in The Lancet shows 82% reduction in infant RSV hospitalizations
Sanofi SA SAN
News
-
Press Release: Annual General Meeting of April 30, 2024
Sanofi Sales, Profit Beat Expectations
Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance
Sanofi Says Blood-Disorder Drug Meets Key Target in Late-Stage Trial
Press Release: Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration
Diabetes medication appears to slow progress of Parkinson's disease in French-backed trial
Press Release: Availability of the Q1 2024 Memorandum for modelling purposes
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
Press Release: Filing of the 2023 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Regeneron, Sanofi Get Speedy FDA Review of Dupixent in COPD
Sanofi Proposes Appointment of New Independent Directors
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Press Release: Sanofi’s Board of Directors proposes the appointment of Clotilde Delbos, Anne-Françoise Nesmes and John Sundy as independent Directors
Denali Therapeutics Shares Fall After ALS Treatment Misses Primary Endpoint
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS